Mark is a serial entrepreneur with a wealth of experience of start-up and early stage businesses and is a director of a number of health and life-science companies, whose technologies range from drug development (anti-cancer) through to medical device development (implantable insulin delivery device).
Over 25 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was sold to Agilent Technologies Inc and is currently a director of the antibody-based therapeutics Company Fusion Antibodies.
Mike is a molecular biologist with 21 years clinical experience and a PhD in transplantation immunogenetics at Oxford and co-founder of Biofortuna. He has 15 years of industrial experience in developing commercial genotyping and phenotyping products in both conventional and lyophilised formats. In addition, Mike creates and designs software and instrumentation.
Geoff is a Fellow of the Institute of Chartered Accountants in England and Wales having qualified with PricewaterhouseCoopers in 1981; he attained his Chartered Tax Adviser qualification in 1984. He is an experienced Finance Director who has served on the Boards of numerous venture capital backed and AIM listed businesses.
He has wide experience of businesses operating in the environmental sector, healthcare, outsourced motor claims handling, drug testing services, IT, medical testing services for LifeCos, manufacturing of emergency services equipment, biotech companies and security solutions. He has also worked in the not for profit sector as Finance Director of a leading environmental charity.
James is an Investment Director at Foresight Group, a leading UK asset manager. He works closely with the boards of a number of UK SME companies as non-executive director, including at present a medical device business and healthcare software company. Prior to Foresight, James was a strategy consultant at Deloitte where he advised businesses in the healthcare, public sector and technology sectors. He has a first class degree in Natural Sciences and Management from Cambridge University.
Before co-founding Biofortuna Ltd, David had 7 years R&D experience in developing complex genotyping solutions within Dynal / Invitrogen Transplant Diagnostics division. David specialised in developing and project managing key projects in macro and microarray technologies. He has a BSc in Genetics from the University of Liverpool.
Prior to joining Biofortuna Harry was a Consultant offering business analysis services to the Pharmaceutical and Life Science sectors. Before this he was Director of Operations at London Genetics, a company providing pharmacogenomic research projects to the pharma and biotech industry. At DxS, a personalized medicine company, he was a Genotyping Project Manager and was responsible for all the genotyping projects within the company. As a Sales Manager at Whatman Bioscience Harry promoted the range of nucleic acid purification services and products. Harry graduated in Manchester where he obtained a BSc in Biological Sciences and an MSc in Biomedical Sciences. He then went on to work as a Clinical Genetic Scientist, initially for Northwick Park Hospital, before moving onto a senior role at Manchester Royal Infirmary.
Lee has over 22 years’ experience, working in large organizations and start-up companies in a variety of technical and leadership positions. Previously Lee held technical positions in Fisons Ltd, AstraZeneca Ltd, Lumitech Ltd, Cambrex Inc, Lonza and L3T. More recently Lee was the Technical Team Leader for Swiss Precision Diagnostics Ltd (JV between Alere and P&G) responsible for the development of the Clearblue® product range and Head of Product Development at Microvisk Ltd responsible for CE-Marking the world’s first MEM’s based POC IVD. Lee has a BSc in Biochemistry from Nottingham Trent University and specializes in enzymatic, immunoassay and molecular IVD development from concept to commercialization.